<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190525</url>
  </required_header>
  <id_info>
    <org_study_id>QoL-MM1016</org_study_id>
    <nct_id>NCT03190525</nct_id>
  </id_info>
  <brief_title>Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma</brief_title>
  <acronym>CLARITY</acronym>
  <official_title>CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC
      QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life
      Questionnaire-Core 30) fatigue scale ratings, independently from other prognostic factors for
      OS in multiple myeloma (MM), including the clinically-based prognostic frailty score.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While quality of life (QoL) and other types of patient-reported Outcomes (PROs) can be
      crucial in the management of RRMM patients, a perusal of the literature indicates a dearth of
      information in this area. PRO is defined by the US Food and Drug Administration (FDA) as &quot;a
      measurement based on a report that comes directly from the patient (i.e., study subject)
      about the status of a patient's health condition without amendment or interpretation of the
      patient's response by a clinician or anyone else. A PRO can be measured by self-report or by
      interview provided that the interviewer records only the patient's response. Until now the
      few studies that have included PRO data have been conducted in newly diagnosed MM patients
      enrolled in randomized controlled trials (RCTs).

      For the purpose of this protocol, we have conducted a systematic review of PRO studies
      conducted in RRMM patients receiving treatments with either Imunomodulatory agents (IMiDs) or
      Proteasome inhibitors (PIs). The search was conducted for studies published from January,
      1990 to July, 2015 and yielded only eight studies published within this timeframe. Three
      studies dealt with bortezomib based regimens, two with thalidomide, and the remaining studies
      with carfilzomib, pomalidomide, and lenalidomide. In all these studies PROs were considered
      as secondary outcomes and in four this was analyzed in the context of RCTs.

      Despite enhanced disease control, none of the current novel agents, either IMiDs or PIs are
      free of significant toxicities, which frequently persist after completing treatment and
      continue to impair patient's daily functioning over the long-term period. Also, it is
      important to consider the poor prognosis for many of these patients. For example, patients
      who fail first-line PIs or IMiDs have been shown to report an average life expectancy of 9
      months from the time of becoming refractory to PIs and IMiDs. Maintaining a &quot;good&quot; or
      &quot;acceptable&quot; level of QoL and lowering symptom burden over the longest possible period of
      time is a main goal of treatment for RRMM patients. Therefore, considering the paucity of QoL
      evidence-base data, CLARITY is designed to expand on some key understudied areas in this
      population that are broadly summarized in the next two paragraphs.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">January 2, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.</measure>
    <time_frame>30 months from study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To devise a patient-centered frailty score for RRMM patients.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the prognostic value of the frailty score in the setting of RRMM.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate QoL over time (outcome measures: EORTC QLQ-C30 and QLQ-MY20) by type of treatment and examine factors that contribute the most in maintaining baseline QoL levels.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate relationship between satisfaction with information provision (outcome measure: EORTC INFO-25) and QoL outcomes (outcome measures: EORTC QLQ-C30 and QLQ-MY20).</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess patients' preferences for involvement in treatment decision-making and the relationships between preferences and patient characteristics.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">367</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Multiple Myeloma patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionnaires</intervention_name>
    <description>QLQ-C30</description>
    <arm_group_label>Multiple Myeloma patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Considering the observational nature of study and fact that we aim to provide data on RRMM
        patients from the real-world setting, we have set up very broad inclusion criteria.
        Patients enrolled in clinical trials are still eligible for this protocol. Possible
        participation in a clinical trial at the time of entry in this study will be recorded and
        used for sensitivity analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MM patients who have received at least 1 prior line of therapy and are considered as
             RRMM according to IMWG criteria.

          -  Adult patients (≥ 18 years old).

          -  Written informed consent provided.

          -  Patients who have been enrolled onto other study therapy protocols are also eligible.

          -  Having a full baseline PRO evaluation completed.

          -  All data a available to calculate the frailty score.

        Exclusion Criteria:

          -  Having any kind of psychiatric disorder or major cognitive dysfunction hampering the
             provision of informed consent.

          -  Having reported any grade ≥3 adverse event within two weeks prior to study entry.

          -  Having received more than 5 lines of therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fabio Efficace</last_name>
    <role>Study Chair</role>
    <affiliation>GIMEMA Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Cavo</last_name>
    <role>Study Director</role>
    <affiliation>S. Orsola Malpighi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Oncologia Medica - A.O. Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia -plesso ospedaliero &quot;A. Tortora&quot; di Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1 TORRE DELLE MEDICINE, 6° piano</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOS di Ematologia Servizio di Immunoematologia e medicina Trasfusionale Azienda Sanitaria Provinciale 7</name>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Università Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia - Presidio Ospedaliero N. Giannetasio - Azienda ASL 3</name>
      <address>
        <city>Rossano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Ematolgia - A.O. &quot; SS Annunziata&quot; - P.O. S.G. Moscati</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa II Medicina - Ematologia - Centro di Riferimento Ematologico - Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London North West Healthcare Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

